Volume 3, Issue 11, November 2025 ISSN (E): 2938-3765

HISTOLOGICAL DEGRADATION PROCESSES OF CARDIOMYOCYTES IN CARDIAC ISCHEMIA

Doston Nodirov
Bakhrom Khudoyberdiyev
Abdumalik Khamidjonov
Muhammad Mustafo Abduvohidov
Asadbek Ruzimboyev
Tashkent State Medical University, Tashkent Uzbekistan

Abstract
Cardiac ischemia initiates a complex sequence of biochemical and structural disturbances that progressively impair the integrity and function of cardiomyocytes. Prolonged oxygen and nutrient deprivation lead to energy depletion, ionic imbalance, mitochondrial dysfunction, and disruption of cellular membranes. These events trigger cytoplasmic swelling, loss of myofibrillar organization, calcium overload, activation of proteolytic enzymes, and ultimately irreversible necrosis. Histologically, ischemic cardiomyocytes demonstrate sarcolemmal rupture, nuclear pyknosis, eosinophilic cytoplasm, loss of cross-striations, and inflammatory cell infiltration. A detailed understanding of these degradation processes is essential for accurate diagnosis, staging of myocardial injury, and developing targeted interventions aimed at minimizing tissue damage and improving clinical outcomes in ischemic heart disease.

Keywords: Cardiac ischemia; cardiomyocyte degradation; histology; mitochondrial dysfunction; calcium overload; necrosis; myocardial injury; cellular pathology.

Introduction

Cardiac ischemia is a pathological condition in which the myocardial tissue receives insufficient oxygen and nutrients due to reduced coronary blood flow. As cardiomyocytes rely heavily on continuous aerobic metabolism, even short periods of ischemia initiate a cascade of metabolic, structural, and functional disturbances. These changes evolve rapidly from reversible cellular alterations to irreversible injury when perfusion is not restored in time.

Histological examination provides critical insights into the sequence of degenerative events occurring within affected cardiomyocytes. Early stages are characterized by cellular swelling, loss of glycogen, mitochondrial dysfunction, and impaired membrane ion transport. As ischemia progresses, intracellular calcium accumulation, proteolytic enzyme activation, and membrane disruption lead to coagulative necrosis, nuclear disintegration, and inflammatory infiltration.

Understanding these microscopic degradation processes is essential not only for identifying the severity and timing of myocardial injury but also for guiding clinical decision-making and improving therapeutic strategies aimed at preserving myocardial viability. This section outlines the fundamental histological changes observed in cardiomyocytes during ischemia and highlights their significance in the pathophysiology of ischemic heart disease.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Main Part

When cardiac ischemia begins, the first structures to react are the cardiomyocytes themselves. The sudden reduction in oxygen supply interrupts normal oxidative metabolism, causing ATP levels to drop rapidly. With less energy available, ion pumps—especially the Na^+/K^+-ATPase—begin to fail. Sodium starts to accumulate inside the cell, water follows it, and the cardiomyocyte becomes swollen and enlarged. At this early stage, one can observe mild cytoplasmic clearing, dilation of the sarcoplasmic reticulum, and a noticeable depletion of glycogen stores. These changes impair contractile function, yet they remain reversible if blood flow is restored in time.

As ischemia continues, mitochondria—highly sensitive to oxygen deprivation—undergo visible structural damage. They lose their membrane potential, their cristae begin to break down, and they become swollen. ATP production decreases even further, pushing the cell toward energetic collapse. These mitochondrial changes represent a crucial turning point, indicating that the cell is nearing irreversible injury.

Without timely reperfusion, the internal ionic balance deteriorates rapidly. Calcium begins to accumulate inside the cell in excessive amounts. This rise in intracellular calcium is particularly destructive, as it activates a variety of proteolytic enzymes. Calpains and other proteases start degrading key structural proteins—including actin, myosin, troponin, and desmin—leading to severe disorganization of the myofibrils. The orderly contractile structure of the cardiomyocyte begins to unravel, and the cell loses its mechanical integrity.

At this stage, the injury becomes irreversible. The sarcolemma can no longer maintain its stability and eventually ruptures. Once the membrane breaks, intracellular enzymes and proteins leak into the surrounding tissue and the bloodstream, marking the onset of coagulative necrosis. Histologically, the cytoplasm becomes intensely eosinophilic, cross-striations disappear, and the nucleus undergoes pyknosis, fragmentation, or complete dissolution. Within several hours, neutrophils begin to infiltrate the necrotic tissue—one of the clearest microscopic indicators of myocardial infarction.

In the peripheral zones of the ischemic region, apoptosis also plays a role. Unlike necrosis, apoptosis is a controlled form of cell death. The affected cardiomyocytes shrink, their nuclei condense and fragment, and small apoptotic bodies form. These fragments are efficiently removed by macrophages. This form of cell death is especially common in chronic or low-grade ischemia.

Over the following days and weeks, the body initiates a repair process. Macrophages clear the necrotic debris, fibroblasts proliferate, and a dense network of collagen fibers gradually replaces the lost cardiomyocytes. The resulting fibrotic scar provides structural stability but reduces the elasticity and contractile potential of the myocardium. As a consequence, chronic remodeling may contribute to long-term heart failure.

Discussion

The histological changes observed in cardiomyocytes during ischemia reveal how quickly and dramatically the heart responds to the loss of oxygen and nutrients. What begins as a reversible metabolic disturbance can transform into irreversible cellular destruction within a relatively short period. This progression underscores the importance of early intervention in clinical practice, where even a few minutes can determine whether myocardial tissue will survive or be permanently lost.

One of the most critical observations is the vulnerability of mitochondria. Their early dysfunction not only signals a decline in energy production but also serves as a trigger for downstream events such as calcium overload and cell death pathways. This highlights why therapies aimed at preserving mitochondrial integrity—such as ischemic preconditioning or pharmacological agents targeting the mitochondrial permeability transition pore—have become important areas of research.

The transition from reversible to irreversible injury also emphasizes the destructive role of calcium dysregulation. Once calcium accumulates beyond a certain threshold, the activation of proteolytic enzymes leads to rapid structural disintegration. This explains why biomarkers like troponin rise sharply in the blood: they reflect the breakdown of contractile proteins and the loss of membrane integrity.

Another important aspect is the coexistence of necrosis and apoptosis. Although necrosis dominates in acute, severe ischemia, apoptosis contributes significantly in border regions and chronic ischemic states. This dual nature of cell death suggests that therapeutic approaches should consider both pathways to effectively limit myocardial loss.

Finally, the long-term remodeling process has major clinical implications. While fibrosis stabilizes the damaged area, it cannot replace the contractile function of the original myocardium. Over time, this can impair ventricular performance and contribute to heart failure. Understanding these histological events helps clinicians better predict patient outcomes and guides the development of strategies to preserve myocardial function after ischemic injury.

Conclusion

The progression of cardiomyocyte damage during cardiac ischemia reflects a tightly connected series of metabolic, structural, and molecular events. What begins as a simple shortage of oxygen rapidly evolves into a cascade of cellular dysfunction, mitochondrial injury, calcium overload, and ultimately irreversible cell death. These microscopic changes not only define the severity of myocardial injury but also shape the long-term clinical outcomes for patients.

Recognizing the timing and nature of these histological processes is essential for improving diagnosis, guiding acute treatment, and developing therapies that can protect the myocardium from further deterioration. Early restoration of blood flow remains the most effective way to preserve cardiomyocyte viability, but emerging strategies targeting mitochondria, ion homeostasis, and cell death pathways offer additional hope.

Ultimately, understanding the histological degradation of cardiomyocytes in ischemia provides a clearer picture of how myocardial infarction develops and progresses. It reinforces the urgent need for rapid clinical response and supports ongoing research aimed at protecting cardiac tissue at the microscopic level, long before the damage becomes clinically irreversible.

References

1. Basso, C., & Thiene, G. (2020). The pathophysiology of myocardial ischemia: Cellular and molecular mechanisms underlying cardiomyocyte injury. Cardiovascular Pathology, 44, 107–115.
2. Finegold, J. A., Asaria, P., & Francis, D. P. (2019). Mortality from ischaemic heart disease: Global trends and future projections. European Heart Journal, 40(29), 2365–2373.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

3. Hausenloy, D. J., & Yellon, D. M. (2013). Myocardial ischemia–reperfusion injury: A neglected therapeutic target. Journal of Clinical Investigation, 123(1), 92–100.
4. Пулатов, Х. Х. (2022). Влияние экспериментального сахарного диабета на надпочечники: дис. Ўзбекистон, Самарқанд.
5. Закиров, А. У., Пулатов, Х. Х., & Исмалов, Д. Д. (2001). Изучение противовоспалительных свойств диклозана. Экспер. и клин. фарм, (5), 50-52.
6. Nishanov, D. A., Kh, P. K., Sobirova, D. R., & Matrasulov, R. S. (2023). MODERN DIAGNOSIS OF NEPHROBLASTOMA IN CHILDREN. Galaxy International Interdisciplinary Research Journal, 11(2), 430-441.
7. Собирова, Д. Р., Нуралиев, Н. А., Усманов, Р. Д., Азизова, Ф. Х., & Пулатов, Х. Х. (2023). СОЯ УНИНИНГ ОЗУҚАВИЙ ҚИЙМАТИ, МИКРОЭЛЕМЕНТЛАР ВА РАДИОНУКЛИДЛАР КЎРСАТГИЧЛАРИ (24-СОНЛИ). «МИКРОБИОЛОГИЯНИНГ ДОЛЗАРБ МУАММОЛАРИ» МАВЗУСИДАГИ РЕСПУБЛИКА ИЛМИЙ-АМАЛИЙ АНЖУМАНИ, 137.
8. Sobirova, D. R., Usmanov, R. D., Po'latov, X. X., Azizova, F. X., & Akbarova, M. N. (2023). QANDLI DABET KASALLIGIDA O 'PKA ENDOTELIYIDAGI GISTOLOGIK O 'ZGARISHLAR.
9. Adilbekova, D. B., Usmanov, R. D., Mirsharapov, U. M., & Mansurova, D. A. (2019). MORPHOLOGICAL STATE OF EARLY POSTNATAL FORMATION OF THE ORGANS OF THE GASTROINTESTINAL TRACT AND LIVER IN OFFSPRING BORN AND RAISED BY MOTHERS WITH CHRONIC TOXIC HEPATITIS. Central Asian Journal of Medicine, 4, 43-55.
10. Ermetov, E. Y., Arzikulov, F., Safarov, U., Olimov, A., & Izbasarov, I. (2025). PROTECTION OF MEDICAL DATA BY BLOCKCHAIN. Western European Journal of Medicine and Medical Science, 3(01), 52-56.
11. Ermetov, E. Y., Arzikulov, F., & Norbutayeva, M. (2025). ELECTRONIC HEALTH SYSTEMS (EHR). Western European Journal of Medicine and Medical Science, 3(01), 12-20.
12. Islomjon, I., & Fazliddin, A. (2025). EFFICIENCY OF MOBILE APPS IN HEALTHCARE: A CASE STUDY OF MED-UZ AI. Modern American Journal of Medical and Health Sciences, 1(2), 19-24.
13. Arzikulov, F., & Makhsudov, V. (2025). HOW TO CALCULATE OPERATIONS ON MATRICES USING EXCEL. Modern American Journal of Engineering, Technology, and Innovation, 1(2), 119-132.
14. Arzikulov, F., & Tolibjonov, L. (2025). THE INTRODUCTION OF BLOCKCHAIN TECHNOLOGIES TO OUR COUNTRY AND THEIR IMPACT ON THE ECONOMY. Web of Discoveries: Journal of Analysis and Inventions, 3(4), 108-111.
15. Ibáñez, B., Heusch, G., Ovize, M., & Van de Werf, F. (2015). Evolving therapies for myocardial ischemia and reperfusion. Journal of the American College of Cardiology, 65(14), 1454–1471.
16. Jennings, R. B., & Reimer, K. A. (2012). Lethal myocardial ischemic injury. American Journal of Pathology, 181(5), 1405–1417.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

17. Lemasters, J. J., Theruvath, T. P., Zhong, Z., & Nieminen, A. L. (2009). Mitochondrial calcium and the permeability transition in cell death. Biochimica et Biophysica Acta (BBA) - Bioenergetics, 1787(11), 1395–1401.
18. Murphy, E., & Steenbergen, C. (2008). Mechanisms underlying acute protection from cardiac ischemia–reperfusion injury. Physiological Reviews, 88(2), 581–609.
19. Ong, S. B., Samangouei, P., Kalkhoran, S. B., & Hausenloy, D. J. (2015). Apoptosis, autophagy, and necrosis in the heart. Journal of Physiology, 593(14), 3275–3300.
20. Thygesen, K., Alpert, J. S., & Jaffe, A. S. (2018). Fourth universal definition of myocardial infarction. Circulation, 138(20), e618–e651.
21. Yellon, D. M., & Hausenloy, D. J. (2007). Myocardial reperfusion injury. New England Journal of Medicine, 357(11), 1121–1135.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5